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remains a global public health concern. There are
approximately 350 million people in the world who are
persistently infected with this virus [1], and they have
higher risks of developing complications of the disease
that can range from mild to chronic hepatitis to the
more advanced disease manifestations which include cir-
rhosis with hepatic decompensation and hepatocellular
carcinoma (HCC). The only means currently to prevent
such complications in individuals who are already
chronically infected with the virus is to control viral rep-
lication and reduce liver damage with the use of inter-
feron-alpha (IFN-a) and or nucleos(t)ide analogs
(NA). Nonetheless, eﬃcacies of these treatment methods
are limited, and there is increasing evidence to suggest
that these limitations are associated with the genetic var-
iability of HBV [2–4].
The HBV genome is complex and has at least four
open reading frames (ORF) that overlap one another
so that the total coding capacity is around one and a
half times the genomic length. This viral family is classi-
ﬁed into eight geographically deﬁned genotypes (A to H)
based on P8% diversity of their entire genome nucleo-
tide sequences. HBV genotypes have signiﬁcant associa-0168-8278/$34.00  2008 European Association for the Study of the Liver.
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noma; NA, nucleos(t)ide analogs; ORF, open reading frames.tions with severity of liver disease, clinical outcome, and
response to antiviral therapies [3]. C-genotype infections
tend to have higher disease progression rates [5,6] and
lower spontaneous HBeAg seroconversion rates [7,8]
than B-genotype infections. C-genotype infections also
require longer for HBeAg seroconversion to take place
[9], thus active infections can persist longer than B-geno-
type infections, and in turn may enhance the develop-
ment of severe liver diseases such as cirrhosis and
HCC. Similarly, chronic infections appear to be more
common with European A-genotype viruses [10], and
A-genotype infections seem less likely to persist after
hepatitis B e antigen (HBeAg) seroconversion [11] when
compared with D-genotype infections. The latter obser-
vation is probably due to the inability for the European
A-genotype viruses to select the G1896A mutation. This
mutation introduces a stop codon in the precore (pc)
gene to inhibit the production of HBeAg, and in turn
allows the virus to evade the immune system of the host.
However, G1896 is in the epsilon region of the prege-
nomic RNA that is involved with RNA encapsidation
and pairs with the nucleotide at genome position 1858.
HBV A-genotype has a cytosine at genome position
1858, thus without a corresponding C1858T mutation,
the G–C bond would prevent a G1896A selection. How-
ever, relationships between clinical outcomes and HBV
genotypes are not always unambiguous. Individuals
infected with the same HBV genotype can exhibit dis-
similar clinical and virological characteristics due to
infections by diﬀerent HBV subgenotypes [12]. Impor-
tantly, some of the subgenotypes were derived by recom-
bination with other HBV genotypes. For example,
Sugauchi et al. [13] classiﬁed HBV B-genotype into BaPublished by Elsevier B.V. All rights reserved.
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was in fact a B-genotype that had a recombination
event(s) with the pc and core regions of C-genotype.
This ﬁnding provided an insight into why individuals
with B-genotype infections can develop HCC at an ear-
lier age than those with C-genotype infections in Taiwan
[14].
IFNs are naturally occurring cytokines primarily pro-
duced by the innate immune system that have antiviral,
antiproliferative and immunomodulatory eﬀects [15]. As
an antiviral agent, IFN-a functions to promote viral
control by immune stimulation and direct cytokine-
mediated suppression of HBV replication [16]. However,
this immune modulator is limited in its use in clinical
practice due to a number of factors: expense, parenteral
administration, signiﬁcant side eﬀects and poor toler-
ance. Thus, knowledge gained by studying the natural
clinical outcomes of infections caused by diﬀerent
HBV genotypes/subgenotypes could be used to predict
potential beneﬁts of IFN-a for individuals infected with
HBV and to improve the overall response rate of this
drug. Inﬂuences that HBV genotypes have on the
response rates of IFN-based treatments (IFN-a and
PEG-IFN-a) have been summarised in a recent review
[4]. The majority of these studies showed consistent ﬁnd-
ings in that European A-genotype infections had higher
response rates to IFN-based therapies compared with
D-genotype infections, and similarly B-genotype infec-
tions had higher response rates than C-genotype infec-
tions. However, HBV genotypes/subgenotypes cannot
be used as the sole predictor for IFN responsiveness
since eﬃcacy of IFN-based treatments is also inﬂuenced
by a number of other factors such as pre-treatment HBV
DNA and alanine aminotransferase (ALT) levels, age,
and the presence of basal core promoter (bcp) and pc
mutations in the viruses [17], as well as human leukocyte
antigen-DRB1 (HLA-DRB1) types in the host [18].
Further explorations of the relationships between these
host as well as viral factors and IFN-a response are
required.
NAs are designed to inhibit the function of HBV
reverse transcriptase (rt), and are widely used for treat-
ing patients with chronic hepatitis B. To date, ﬁve
NAs have been licensed for treatment (lamivudine/
LMV, telbivudine/Ld-T, entecavir/ETV adefovir/
ADV, and tenofovir/TDF). Although these drugs are
highly eﬀective in viral replication control, eﬃcacy is
often hindered by the selection of drug-resistant viruses.
The primary resistance mutations have been identiﬁed
for LMV [19], Ld-T [20], ETV [21] and ADV [22], and
they are all conﬁned to eight HBV-rt codons (169,
180, 181, 184, 202, 204, 236 and 250) [23]. However,
some of these primary resistance mutations can compro-
mise viral replication ﬁtness, and to compensate, these
particular HBV mutants would often co-select other rt
mutations to partially restore replication eﬃciency.Most compensatory mutations reported to date are
associated with LMV resistance (LMVr); and rtL180M
is the most widely reported. While rtL180M alone does
not aﬀect LMV susceptibility, the level of LMVr does
increase substantially when co-selected by rtM204V
mutants (153- to P10,000-fold increase in EC50 com-
pared to wild-type virus) [19]. Interestingly, rtL180M is
nearly always co-selected with rtM204V mutants while
prevalence for rtL180M+rtM204I mutants is compara-
tively lower. In contrast, rtL80I/V is commonly co-
selected by rtM204I mutants. The association between
infection with rtL80I/V HBV and severe liver disease in
C-genotype infections was ﬁrst noted by Ogata et al.
[24], but the ability of the rtL80I/V change to enhance
the replication eﬃciency of rtM204I/V mutants has only
been conﬁrmed recently [25]. This latter study also
showed rtL80I/V occurs almost exclusively in association
with LMVr, and co-selection with rtM204I or rtM204V
occurred in approximately 46% and 9% of the HBV
sequences respectively using a large database [26].
Another important compensatory mutation associated
with LMVr is rtV173L, and this change is nearly always
detected in association with rtL180M and rtM204V
mutations. Prevalence for the ‘‘triple” rtV173L+
rtL180M+rtM204V mutant is overall low, but its inci-
dence rate varied signiﬁcantly between immuno-compe-
tent (mono-infection – 9%) and immuno-suppressed
(liver transplantation/ HIV co-infection – 20%) individu-
als with LMVr chronic HBV infections [27]. These viral
mutants can replicate at approximately 90% eﬃciency
of the wild-type viruses, while the rtL180M+rtM204V
mutants could only replicate at 40% eﬃciency. More
importantly, the rtV173L and rtM204V changes in the
‘‘triple mutant” result in two corresponding hepatitis B
surface antigen (HBsAg) changes (sE164D and sI195M)
due to the overlapping nature of HBV genomes. Such
mutants with both HBsAg changes have markedly
reduced anti-HBs binding ability to the HBsAg [28],
which suggests potential vaccine-escape characteristics.
This is a serious public health concern since there is
increased likelihood that these drug-associated mutants
will propagate among the vaccinated individuals, particu-
larly in the setting of HIV infection.
Cross- and multi-drug resistance further complicate
the issue of HBV drug resistance. Some rt mutations
can exhibit high levels of cross-resistance between NAs
[20], and can accumulate over time to produce complex
mutation patterns leading to multi-drug resistance.
Nonetheless, the ability to discover novel drug resistance
proﬁles for HBV is limited due to the large variations of
rt mutation patterns that can occur (naturally occurring
and drug-associated mutations) in HBV isolates.
In this issue of the Journal, Svicher et al. [29] addressed
this problem by using a combination of statistics and
advanced data mining techniques to identify two distinc-
tive HBV mutation clusters that are associated with
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cohort of 89 LMV-failing patients (61 HBV mono-infec-
tions and 28 HIV/HBV co-infections), trend analysis
showed HIV/HBV co-infected patients tended to be
younger, had a lower proportion of negative serum
HBeAg, and required less time to develop LMVr. These
ﬁndings correlated with previous European studies
[10,11] when the data were stratiﬁed in the context of
HBV genotypes – higher prevalence forA-genotype infec-
tions was noted among the HIV/HBV co-infected
patients (57%), and D-genotype infections for the HBV
mono-infected patients (90.1%). Importantly, clustal
analysis of LMVr associated mutations revealed
rtM204V mutants always co-select rtL180M, and have a
tendency to occur with other mutations in the HBV-rt B
domain such as rtV173L and rtT184A/S, which are also
associated with ETV resistance [21]. In contrast, rtM204I
alone is suﬃcient to result inLMVr, but viralmutants that
carry this mutation can occur with other mutations such
as those in the HBV-rt A domain, including rtS53N,
rtT54Y and rtL80I/V. Interestingly, preferences for these
two distinct LMVr mutation clusters diﬀer between the
two HBV genotypes studied – A-genotype preferentially
select rtM204V (68.2%) while D-genotype showed similar
prevalence for rtM204V(39.1%) and rtM204I (45.3%).
Another important contribution made by this study is
the demonstration that these datamining techniques used
can be applied to analyse the interactions between HBV
polymerase and envelope during antiviral treatments.
Data exploratory techniques have been utilised to
study drug resistance mutation proﬁles in HIV for a
number of years, but only recently for HBV [26].
One of the earliest studies conducted in the HIV area
was by Gonzales et al. [30] who used two advanced
data mining methods, binomial (phi) correlation coeﬃ-
cient calculations and principal component analysis, to
aid in the identiﬁcation of novel mutations that may be
associated with cross- and multi-drug resistance in anti-
retroviral therapy. Using experiences gained in similar
HIV drug resistance studies, Svicher et al. [29] demon-
strated that these data exploratory techniques can also
be applied to study HBV drug resistance proﬁles.
Another tool available for antiretroviral research that
can also beneﬁt HBV drug resistance studies is the
public database and datamining system hosted by Stan-
ford University [31], a central location where data can
be pooled and utilised by all researchers. Combining
such public database systems and advanced data min-
ing methods [26] will enable HBV researchers to fur-
ther study and explore relationships between disease
progression, drug-associated rt mutations as well as
corresponding HBsAg mutations, and can contribute
signiﬁcantly to the development of treatment algo-
rithms which can be used for better management of
patients with chronic hepatitis B.References
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